CLDX Stock Analysis: Buy, Sell, or Hold?
CLDX - Celldex Therapeutics, Inc
$33.41
0.98 (3.02%)
▲
5d:
+6.84%
30d:
+8.12%
90d:
+8.12%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When CLDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CLDX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CLDX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CLDX is currently trading at $33.41, which is considered extended relative to its 30-day fair value range of $29.52 to $32.12.
Technical Outlook: Technically, CLDX is in a uptrend. The price is approaching resistance at $34.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: CLDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.53 (+72.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLDX is in a uptrend. The price is approaching resistance at $34.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: CLDX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.53 (+72.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$29.52 -
$32.12
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 72.2% below Wall St target ($57.53)
Trading Range Analysis
30-Day Trading Range
$29.52 -
$32.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$28.38
Resistance Level
$34.14
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.43
Wall Street Target
$57.53
(+72.2%)
Revenue Growth (YoY)
-97.8%
Share & Embed Analysis
Last updated: June 23, 2026 2:20 AM ET
Data refreshes hourly during market hours. Next update: 3:20 AM
Data refreshes hourly during market hours. Next update: 3:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 56 HOLD |
